Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 6Neoplasms 3Neoplasm Metastasis 3Recurrence 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Head and Neck Neoplasms 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Nephrotic Syndrome 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Locally Advanced Bladder Cancer 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Diseases 1Hepatitis B 1Gastrointestinal Diseases 1Familial Mediterranean Fever 1Esophageal Neoplasms 1Depression 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Brain Neoplasms 1Arthritis, Rheumatoid 1Anxiety Disorders 1

Interventions

avelumab 2Sunitinib 2Nutrition Assessment 2Blood Specimen Collection 2Axitinib 2trifluridine tipiracil drug combination 1trebananib 1spartalizumab 1pembrolizumab 1etelcalcetide hydrochloride 1enzalutamide 1bicalutamide 1aldesleukin 1Stents 1Sorafenib 1Sodium Bicarbonate 1Resistance Training 1Receptors, Androgen 1Plasma Exchange 1Pharmaceutical Preparations 1Paclitaxel 1Oxaliplatin 1Nephrotomy 1Nephrostomy, Percutaneous 1Lysine Acetyltransferase 5 1Leuprolide 1Kidney Transplantation 1Interleukin-2 1Goserelin 1Flutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Kidney Diseases × Pharmaceutical Preparations × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡